M.D. Anderson Cancer Center: Lymphoma, Mantle-Cell trials

The registry lists 35 Lymphoma, Mantle-Cell studies with M.D. Anderson Cancer Center as lead sponsor. 2 are open to participants now and 7 have results posted.

Early Phase 1 2Phase 1 12Phase 2 26No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) PatientsRecruitingNCT06263491Phase 2
• Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) PatientsRecruitingNCT05529069Phase 2
• Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell LymphomaTerminatedNCT04047797Phase 2Results posted
• Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's LymphomaCompletedNCT03019640Phase 2Results posted
• Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaTerminatedNCT02420795Phase 1/2Results posted
• A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell LymphomaTerminatedNCT02042950Phase 2Results posted
• Study of Bortezomib in Combination With Cyclophosphamide and RituximabCompletedNCT00958256Phase 2Results posted
• Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell LymphomaCompletedNCT00477412Phase 1/2Results posted
• Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell LymphomaCompletedNCT00294632Phase 1/2Results posted
• GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell LymphomaActive, not recruitingNCT06522386Phase 2
• A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell LymphomaActive, not recruitingNCT05495464Early Phase 1
• ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin LymphomaActive, not recruitingNCT05025800Phase 1/2
• Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell LymphomaWithdrawnNCT04990778Phase 2
• Interrogating Biological Signaling Pathway Dysregulations and In Vitro Screening With Personalized Therapies in Relapsed or Refractory Mantle Cell Lymphoma, MCL MATCH TrialCompletedNCT04872413Not applicable
• Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell LymphomaActive, not recruitingNCT04765111Phase 2
• Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell LymphomaActive, not recruitingNCT04189757Phase 2
• Ultra Low Dose Radiation Delivered Before or After Chemotherapy-Free Targeted Therapy in Treating Patients With Relapsed or Refractory Mantle Cell LymphomaActive, not recruitingNCT04054167Phase 2
• Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell LymphomaActive, not recruitingNCT03946878Phase 2
• Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell LymphomaActive, not recruitingNCT03710772Phase 2
• Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell TransplantActive, not recruitingNCT03622788Phase 1/2
• CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell LymphomaWithdrawnNCT03579927Phase 1/2
• CD19-Specific T Cells Post AlloSCTTerminatedNCT03579888Phase 1
• Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell LymphomaActive, not recruitingNCT03282396Phase 2
• Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell LymphomaWithdrawnNCT03232307Phase 2
• Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell LymphomaCompletedNCT03219047Early Phase 1
• Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell LymphomaActive, not recruitingNCT02427620Phase 2
• Infusion of Allogeneic, 3rd Party CD19-specific T CellsWithdrawnNCT02274506Phase 1
• Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell LymphomaTerminatedNCT02269085Phase 1
• Carfilzomib Consolidation Therapy After Autologous Stem Cell Transplantation (ASCT) for Mantle Cell Lymphoma (MCL), T-cell Lymphoma (TCL), and Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT01926665Phase 1
• Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell LymphomaActive, not recruitingNCT01880567Phase 2
• Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell TransplantCompletedNCT00880815Phase 1
• Combined CT Colonography and PET Imaging in Mantle Cell LymphomaWithdrawnNCT00541424
• RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell LymphomaCompletedNCT00081874Phase 1/2
• Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell LymphomaCompletedNCT00038623Phase 2
• Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell LymphomaCompletedNCT00003311Phase 2